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Food-triggered anaphylaxis can encompass a variety of
symptoms that affectmultiple organ systems and can be
life threatening. The molecular distinction between
non–life-threatening and life-threateningmodes of such
anaphylaxis has not yet been delineated. In this study,
we sought to identify the specific immune functions that
regulate the severity of oral antigen-induced anaphylaxis.
We thus developed an experimental mouse model in
which repeated oral challenge of ovalbumin-primedmice
induced an FcRI- and IgE-dependent oral antigen-trig-
gered anaphylaxis that involved multiple organ systems.
Strikingly, the severity of the systemic symptoms of ana-
phylaxis (eg, hypothermia) positively correlated with the
levels of intestinal mast cells (r  0.53; P < 0.009). In
addition, transgenic mice with both increased intestinal
andnormal systemic levels ofmast cells showed increased
severity of both intestinal and extra-intestinal symptoms
of IgE-mediated passive as well as oral antigen- and IgE-
triggered anaphylaxis. In conclusion, these observations
indicate that the density of intestinal mast cells controls
the severity of oral antigen-induced anaphylaxis. Thus, an
awareness of intestinal mast cell levels in patients with
food allergies may aid in determining their susceptibility
to life-threatening anaphylaxis and may eventually aid in
the treatmentof food-triggeredanaphylaxis. (Am J Pathol
2012, 180:1535–1546; DOI: 10.1016/j.ajpath.2011.12.036)
Severe food allergy-related reactions, termed food-trig-
gered anaphylaxis, are serious, life threatening, and re-
sponsible for 30,000 to 120,000 emergency department
visits, 2000 to 3000 hospitalizations, and 150 deaths
per year in the United States.1,2 Clinical studies indicatethat food reactions account for 30% to 75% of anaphy-
lactic cases in emergency departments in North America,
Europe, Asia, and Australia.1,3–5 The onset of symptoms
from food-induced anaphylaxis is variable, occurring
within seconds to a few hours after exposure to the ca-
sual food allergen, and often affects multiple organ sys-
tems, including gastrointestinal, cutaneous, respiratory,
and cardiovascular systems.6 Cutaneous symptoms (ur-
ticaria and angioedema) are the most common, occur-
ring in 80% of cases, whereas cardiovascular involve-
ment occurs in 39% of food allergic reactions.6 Notably,
20% of cases do not present with skin findings, particu-
larly cases of food reaction in children.7
At present, the laboratory tests to support the clinical
diagnosis of an anaphylactic episode have intrinsic limi-
tations. In addition, no reliable method is currently avail-
able to distinguish between atopic persons who do not
have increased risk of anaphylaxis and atopic persons
who have increased risk of anaphylaxis and possible
fatality.8 Furthermore, because patients with food-trig-
gered anaphylaxis do not generally present with a con-
sistent constellation of symptoms, determination of sus-
ceptibility and severity of food-induced anaphylaxis
cannot necessarily be predicted on the basis of clinical
history.9,10
Clinical and experimental analyses have identified a
central role for IgE/FcR/mast cells and mast cell-derived
mediators, including histamine, platelet-activating factor,
serotonin, proteases (tryptase and chymase), and lipid-
derived mediators [prostaglandin D2 and leukotrienes
(leukotriene C4, leukotriene D4, and leukotriene E4)] in
promoting the clinical manifestations associated with
food-triggered anaphylaxis.11–17 However, the relative
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and systemic manifestations of anaphylaxis and how it re-
lates to the clinical presentation of food-triggered life-threat-
ening and non–life-threatening anaphylaxis is not yet fully
delineated. The lack of clinical diagnostic tests for anaphy-
laxis and lack of risk stratification criteria to distinguish life-
threatening from non–life-threatening anaphylaxis may re-
flect this incomplete understanding.
In the present study, we developed an experimental
model of oral antigen-induced anaphylaxis in which oral
antigen challenge of mice promotes an anaphylactic re-
action characterized by multiorgan involvement (gastro-
intestinal, cutaneous, respiratory, and cardiovascular
systems). We used this model to begin identifying influ-
ential effector functions important in regulating anaphy-
laxis severity. We show that gastrointestinal, cutaneous,
and cardiovascular symptoms are IgE/mast cell depen-
dent, whereas the induction of airway hyperresponsive-
ness (AHR) can occur in the absence of IgE/mast cell
activation. We show that development of systemic symp-
toms of anaphylaxis positively correlates with intestinal
mast cell levels. Importantly, we show that increased
intestinal mast cell number is associated with increases
in both intestinal and systemic anaphylaxis severity.
Materials and Methods
Mice
Six- to 8-week-old BALB/c wild-type (WT), FcRI, and
intestinal IL-9 transgenic (iIL9Tg) mice were used as pre-
viously described.18,19 BALB/c mice were obtained from
the National Cancer Institute (Bethesda, MD). All mice
were maintained in a barrier facility, and animals were
handled under approved protocols of the Institutional
Animal Care and Use Committee from Cincinnati Chil-
dren’s Hospital Medical Center.
Reagents
Hybridomas were obtained from the following sources:
2.4G2 (rat IgG2b anti-mouse FcRII/III mAb) and anti-
trinitrophenyl (TNP)-IgE (mouse IgE mAb clone IGELa2)
from ATTC (Rockville, MD),20,21 EM-95 (rat IgG2a anti-
mouse IgE mAb)22 from Zelig Eshhar (Rehoveth, Israel),
and rat IgG2a (GL117) and rat IgG2b (J1.2) control mAbs
from Dr. John Abrams (DNAX Research Institute, Palo
Alto, CA). The anti-FcRII/III antibody (clone 2.4G2) is
specific for the extracellular domains of murine FcRIIb
and FcRIII.20 The anti-IgE antibody (clone EM-95) recog-
nizes a domain of the -chain of IgE that is not blocked by
the binding of IgE to FcRI.23 The anti-CD4 depleting anti-
body (clone GK1.5) binds to the surface molecule L3T4/
CD4 and depletes CD4 T cells.24,25 The monoclonal anti-
bodies were purified from ascites produced by the
hybridomas in pristane-primed athymic nude mice by am-
monium sulfate precipitation followed by diethylaminoethyl-
cellulose ion exchange chromatography as previously de-
scribed.26 All antibodies were diluted in normal saline to a
final volume of 200 L per mouse, unless otherwise stated.Passive Anaphylaxis
Mice were injected intravenously (i.v.) with 10 g of anti-
IgE (EM-95) or 500 g of anti-FcRII/III (2.4G2) or control
Ig (GL117, 10 g/200 mL saline; or J1.2, 500 g/200 mL
saline, respectively), and the severity of shock was as-
sessed by rectal temperature with a rectal probe.17,27
Passive Oral Antigen-Induced Anaphylaxis
Mice were injected i.v. with 10 g of anti-TNP-IgE or
control Ig (200 mL of saline). Twenty-four hours later,
mice were held in the supine position and orally gavaged
with 250 L of TNP-bovine serum albumin (BSA; 50 mg)
in saline. Before the intragastric (i.g.) challenge, mice
were deprived of food for 3 to 4 hours. Challenges were
performed with i.g. feeding needles (01-290-2B; Fisher
Scientific Co., Pittsburgh, PA). Rectal temperatures were
measured before and 60 minutes after ovalbumin (OVA)
challenge. Evidence of secretory diarrhea was assessed
by determination of short-circuit current (Isc) of small
intestinal segments ex vivo in the Ussing chamber system
up to 60 minutes after i.g. challenge. Severity of shock
was assessed by rectal temperature with a rectal
probe.17,27
Oral Antigen-Induced Intestinal Anaphylaxis
Four- to 8-week-old mice were sensitized with 50 g of
OVA and 1 mg of alum in sterile saline by intraperitoneal
(i.p.) injection. Beginning 2 weeks later, mice were held in
the supine position three times a week for 3 weeks and
orally gavaged with 250 L of OVA (50 mg) in saline or
250 L of saline [vehicle (Veh)]. Before each i.g. chal-
lenge, mice were deprived of food for 3 to 4 hours.
Challenges were performed with i.g. feeding needles (01-
290-2B; Fisher Scientific Co.). Rectal temperatures were
measured before and 60 minutes after OVA challenge.
Diarrhea was assessed by visually monitoring mice for up
to 60 minutes after i.g. challenge. Mice showing profuse
liquid stool were recorded as diarrhea-positive. Evidence
of secretory diarrhea was assessed by determination of
Isc of small intestinal segments ex vivo in the Ussing
chamber system up to 60 minutes after i.g. challenge.
Unless stated, all measurements of parameters of ana-
phylaxis were measured after the seventh challenge. In
some experiments mice were treated with anti-CD4 anti-
body (GK1.5; 1 mg/200 L i.p.) 24 hours before the
seventh challenge. CD4 T-cell depletion was analyzed
by flow cytometric analyses. Splenic CD4 T cells were
reduced by 95%.
Solutions and Drugs
The Krebs buffer used on each side of the Ussing cham-
ber contained 4.70 mmol/L KCl, 2.52 mmol/L CaCl2,
118.5 mmol/L NaCl, 1.18 mmol/L NaH2PO4, 1.64 mmol/L
MgSO4, and 24.88 mmol/L NaHCO3. The tissues were
allowed to equilibrate for 15 minutes in Krebs buffer that
contained 5.5 mmol/L glucose. All reagents were ob-
Mast Cells Control Anaphylaxis Severity 1537
AJP April 2012, Vol. 180, No. 4tained from Sigma-Aldrich (St Louis, MO) unless stated
otherwise.
Ussing Chambers
One-centimeter, freshly isolated, serosal-stripped seg-
ments of jejunum were mounted between the hemi-cham-
bers of an Ussing apparatus (U2500 Dual Ussing cham-
ber; Warner Instruments, Hamden, CT), and 0.112 cm2 of
tissue was exposed to 10 mL of Krebs buffer at 37°C. The
transepithelial potential difference was detected with two
paired electrodes that contained 4% agar in 3 mol/L KCl.
The electrodes were connected to a voltage clamp am-
plifier (EC-800, Epithelial voltage clamp; Warner Instru-
ments). The electrode potential difference and fluid re-
sistance were compensated before mounting tissue
segments into the chamber. To establish equilibrium, po-
tential difference was continuously monitored under
open-circuit conditions for 15 minutes. Thereafter, the
tissues were voltage-clamped at 0 mV while continuously
measuring Isc. Voltage pulses (3-mV square waves sus-
tained for 5 seconds) were delivered every 50 seconds to
yield a current response for calculation of transepithelial
resistance (TER) from Ohm’s law. For ion conductance
experiments, changes in Isc were determined for the
cumulative addition of forskolin and acetylcholine to the
serosal reservoir. After the peak response to the final
concentration of each agonist was recorded, the Krebs
buffer on each side of the chamber was replaced, and
the tissue was allowed to equilibrate for 30 minutes. Im-
mediately after re-equilibration, tissue was preincubated
with ion channel blockers [4,4=-Diisothiocyano-2,2=-stil-
benedisulfonic acid (DIDS) 100 mol/L or CFTRInh172 20
mol/L to mucosal reservoir], and changes in Isc were
measured in response to the addition of forskolin to the
mucosal side.
Intestinal Mast Cell Quantification
Jejunum tissue was collected 7 to 10 cm distal to the
stomach, whereas ileum and colon samples were col-
lected 1 cm proximal or distal of the cecum. All samples
were fixed in 10% formalin and processed by standard
histologic techniques. The 5-m tissue sections were
also stained for mucosal mast cells with chloroacetate
esterase (CAE) activity as described elsewhere28 and
lightly counterstained with hematoxylin. At least four ran-
dom sections per mouse were analyzed. Quantification of
stained cells was performed by counting the number of
CAE cells from 25 to 50 fields of view (magnification,
40). In some experiments matched samples were fixed
in 4% paraformaldehyde and processed as described
above, and mast cells were quantified to confirm accu-
rate mast cell assessment.
Respiratory Status Measurements
Airway resistance was measured with the use of baro-
metric plethysmography and the flexiVent system (Scireq
Scientific Respiratory Equipment, Inc., Montreal, QC). For
determination of responsiveness to methacholine bybarometric plethysmography, mice were placed, unre-
strained, in cylindrical Plexiglas plethysmograph cham-
bers that were connected to a nebulized control aerosol
delivery system and a Max II apparatus for analyzing
barometric plethysmography (Buxco Research Systems,
Wilmington, NC). Baseline measurements of enhanced
pause29 were made over a 5-minute period. Mice were
then challenged for 3 minutes by inhalation of aerosolized
-methacholine in PBS, produced with a nebulizer
(model 5500D-030; DeVilbiss Healthcare, Somerset, PA),
starting at a methycholine concentration of 0.8 mg/mL.
Enhanced pause measurements were made for 5 min-
utes, starting 2 minutes after completion of exposure to
the aerosolized methacholine, and average enhanced
pause values for the 5-minute period were calculated.
The procedure was then serially repeated with methacho-
line at concentrations of 1.6, 3.2, 6.4, 12.8, and 25.6
mg/mL. Airway responsiveness to methacholine of anes-
thetized, intubated mice was also performed with a
flexiVent apparatus (Scireq Scientific Respiratory Equip-
ment, Inc.). Briefly, the mice were anesthetized, a trache-
otomy was performed, and a cannula was inserted. A
positive end-expiratory pressure of 0.2 kPa was estab-
lished. Saline aerosol followed by -methylcholine (25 to
100 mg/mL; Sigma-Aldrich) established control baseline.
Aerosols were generated with an ultrasonic nebulizer
(UltraNeb 2000; DeVilbiss Healthcare) and delivered to
the inspiratory line of the FlexiVent. Each aerosol was
delivered for 20 seconds during which time regular ven-
tilation was maintained. Five measurements were made
at 25-second intervals, and three peak responses were
compared with the mean response of the saline aerosol
as previously described.30,31
BALF Analysis
OVA- or control (Veh)-challenged mice were sacrificed,
the trachea was cannulated after midline neck incision,
and the lungs were lavaged twice with 0.8 mL of normal
saline containing 0.5 mmol/L EDTA. The recovered bron-
cho-alveolar lavage fluid (BALF) was centrifuged at
400  g for 10 minutes at 4°C, the supernatant fluid was
removed, and mast cell protease (Mcpt-1) levels were
assessed by enzyme-linked immunosorbent assay as de-
scribed by the manufacturer (eBioscience, San Diego,
CA). The BALF cells were counted with a hematocytom-
eter. Cytospin preparations were stained with Diff-Quick
(Dade Diagnostics of Puerto Rico Inc., Aguada, Puerto
Rico). In some experiments lung tissue representing the
central (bronchi/bronchiole) and peripheral (alveoli) air-
ways were fixed in 10% phosphate-buffered formalin with
standard histologic techniques and stained with H&E for
histologic analyses.
Vascular Permeability
Evans blue tissue extravasation was performed as previ-
ously described.32 Briefly, mice received Evans blue dye
in PBS (20 mg/kg, i.v.); 3.5 hours later, mice were anes-
thetized with pentobarbital (20 mg/kg, i.p.), and heart
perfusion was performed (10 mL of PBS arterial perfu-
i.g. Veh-
.05 or **
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250 L of formamide, and incubated overnight at 37°C.
The tissue was centrifuged at 14,000 rpm for 15 minutes
at room temperature. The supernatant fluid was removed,
and absorbance was measured at 650 nm. Tissue protein
levels were quantified with a BCA protein assay kit per
the manufacturer’s instructions (Pierce, Rockford, IL). Ev-
ans blue extravasation was calculated as microgram of
Evans blue per milligram of total protein.
Statistical Analysis
Data are expressed as mean  SEM, unless otherwise
stated. Statistical significance comparing different sets of
mice was determined by Student’s t-test. In experiments
that compared multiple experimental groups, statistical
differences between groups were analyzed with the one-
way, nonparametric analysis of variance and a Bonferroni
posttest. P  0.05 was considered significant. Spear-
man’s rank coefficients were used to quantify the rela-
tions between intestinal mast cell levels and maximum
Figure 1. Intestinal symptoms in oral antigen-triggered anaphylaxis. A: Or
mean number of mast cells per high-power field (hpf) (C) in the small intest
fractions in panel B represent the number of mice that experienced diarrhe
stimulated (F) changes in Isc (Isc) in jejunum segments of OVA-sensitized,
mean  SEM; n  6 to 10 mice per group. Statistical significance is *P  0temperature change. All analyses were performed withPrism 5.0 software (GraphPad Software Inc., San Di-
ego, CA).
Results
Intestinal and Systemic Involvement in Oral
Antigen-Induced Anaphylaxis
To begin deciphering the molecular pathways that mod-
ulate severity of food-triggered anaphylaxis, we devel-
oped a murine model of oral antigen-triggered anaphy-
laxis that has both intestinal and systemic manifestations.
BALB/c WT mice were primed i.p. with OVA/alum and
subsequently challenged by repeated oral gavage with
OVA or with saline (Figure 1A). Repeated oral gavage
induced evidence of anaphylaxis by the fourth challenge,
whereby 50% of the mice had diarrhea within 60 min-
utes of oral gavage. The occurrence of diarrhea in-
creased after the subsequent fifth to seventh challenges,
and by the eighth challenge 100% showed diarrhea (Fig-
ure 1B). We chose to focus our analyses for evidence of
n-triggered anaphylaxis experimental regime. Diarrhea occurrence (B) and
VA-sensitized, i.g. Veh- or OVA-challenged BALB/c WT mice. The common
e number of total mice challenged. TER (D), Isc (E), and -methylcholine-
or OVA-challenged (seventh challenge) BALB/c WT mice. Values represent
P  0.01.al antige
ine of O
a over thintestinal and systemic anaphylaxis after the seventh
xiVent s
*P  0
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response (diarrhea). This was the first challenge whereby
90% of mice experienced diarrhea (Figure 1B). Assess-
ment of other features of intestinal symptoms of anaphy-
laxis after the seventh challenge showed a pronounced
intestinal mastocytosis (Figure 1C). Oral antigen-induced
secretory diarrhea is caused by net chloride (Cl	) secre-
tion (basolateral ¡ lumen flux) and is indicated by an
increased transmural Isc.33–35 To ascertain whether oral
antigen challenge induced secretory diarrhea, the jeju-
num of Veh- and OVA-challenged mice was excised after
the seventh oral challenge, and TER and Isc were deter-
mined. TER was significantly decreased in jejunum from
OVA-challenged WT mice compared with Veh-treated
WT mice, indicating increased intestinal permeability
(Figure 1D). Furthermore, OVA-challenged WT mice had
a significant increase in the basal Isc and Isc after
cholinergic (-methylcholine) stimulation compared with
Veh-treated WT mice (Figure 1, E and F). Collectively,
these results indicate that oral antigen challenge pro-
motes an intestinal mastocytosis and secretory diarrhea.
Assessment of systemic signs and symptoms after the
seventh OVA challenge to OVA-primed BALB/c WT mice
showed induction of cutaneous and mesenteric vascular
leak as evidenced by increased Evans blue extravasation
and associated hypothermia (Figure 2, A and B). Assess-
ment of respiratory status found increased airway
responsiveness to cholinergic (-methacholine) stimula-
tion in the OVA-gavaged OVA-primed WT mice com-
Figure 2. Systemic manifestations in oral antigen-triggered anaphylaxis. A: B
L/PBS) and were subsequently challenged with OVA. Sixty minutes after OV
in the ear (cutaneous) and intestine (mesenteric). Temperature change from 0
the seventh i.g. Veh or OVA challenge in OVA-sensitized WT mice. C: Airway
with the use of whole-body plethysmography and invasive technique (fle
as mean  SEM; n  4 to 8 mice per group from triplicate experiments.pared with saline-gavaged OVA-primed animals as mea-sured by barometric plethysmography and by an
invasive technique (Figure 2C). Histologic analyses of the
lung and BALF analyses showed that the AHR response
occurred independently of a pulmonary cellular infiltrate
(Veh versus OVA, 16.0  1.6 BALF cells 104 cells/mL
versus 11.0  3.4 BALF cells 104 cells/mL; mean  SE;
n  4 mice per group; Figure 2D). Notably, although no
pulmonary cellular infiltrate was observed, levels of the
mast cell activation marker, Mcpt-1, were significantly
elevated in the BALF fluid of OVA-gavaged OVA-primed
WT mice compared with saline-gavaged OVA-primed an-
imals (Figure 2E). These data show that oral antigen-
triggered anaphylaxis is associated with the develop-
ment of systemic disease.
FcRI/IgE Involvement in Intestinal and Systemic
Manifestations of Oral Antigen-Induced
Anaphylaxis
Clinical evidence indicates that food-triggered anaphy-
laxis is mediated by an IgE/mast cell-mediated path-
way.11–17 Previous investigations by us and others indi-
cate that systemic anaphylaxis in mice can be mediated
by either an IgE pathway that involves mast cells or a
pathway that involves IgG, FcRIII, macrophages, baso-
phils, and platelet-activating factor.36,37 To further delin-
eate the role of IgE in the intestinal and systemic symp-
toms of oral antigen-induced anaphylaxis, WT and
e seventh OVA challenge, mice received i.v. injection of 2% Evans Blue (200
nge, the mice were sacrificed, and Evans blue concentration was determined
inutes (B), lung function (C), histology (D), and BALF Mcpt-1 levels (E) after
y to methacholine was measured 30 minutes after the seventh OVA challenge
ystem). D: Original magnification, 40. Data in A and C are represented
.05; **P  0.01.efore th
A challe
to 60 m
reactivitFceRI	/	 mice were sensitized i.p. with OVA/alum and
ody ple
ot signif
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Notably, WT, but not FceRI	/	, mice had diarrhea and
were hypothermic 1 hour after the seventh oral gavage,
indicating that oral antigen-induced intestinal and cardio-
vascular involvement depends on FcRI/IgE signaling
(Figure 3A). Importantly, the level of intestinal mast cells
between WT and FceRI	/	 mice was equivalent, indicat-
ing that the abrogation of intestinal and cardiovascular
symptoms was not because of mast cell deficiency (Fig-
ure 3B). To confirm lack of mast cell activation in
FceRI	/	 mice we assessed serum mcpt-1 levels. We
observed no significant increase in serum mcpt-1 in
FceRI	/	 mice after oral gavage challenge (WT control,
74.0  10.0 ng/mL; WT OVA, 25,858.0  2736.0 ng/mL*;
FceRI	/	 OVA, 69.3  12.6 ng/mL; mean  SEM; n  3
to 12 mice per group; *P 0.001). Histologic assessment
of intestinal mast cells showed remnants of extracellular
mast cell granules (CAE granules) in the lamina pro-
pria of the small intestine of WT OVA mice, whereas
mast cells in FceRI	/	 mice remained intact and gran-
ules were confined within the cytoplasm (see Supple-
mental Figure S1 at http://ajp.amjpathol.org). These
data indicate that oral gavage challenge induces local
intestinal mast cell degranulation that depends on
FcRI/IgE-signaling.
Surprisingly, although the diarrhea and hypothermia
were attenuated in FceRI	/	 mice, we observed no dif-
ferences in AHR between OVA-challenged WT and
FceRI	/	 mice as measured by barometric plethysmog-
raphy and by an invasive technique (Figure 3C; see also
Supplemental Figure S2 at http://ajp.amjpathol.org). Thus,
the FcRI/IgE pathway is important in intestinal and car-
diovascular symptoms; however, it is not required for the
AHR response associated with oral antigen-triggered
anaphylaxis. Studies with mouse models of allergic air-
Figure 3. Intestinal and systemic manifestations of food-triggered anaphyla
(A) and mast cells per high-power field (HPF) in small bowel in WT and Fc
developed diarrhea. C: Lung function in OVA-sensitized, i.g. Veh- or OVA-c
30 minutes after the seventh Veh or OVA challenge with the use of whole-b
8 mice per group from duplicate experiments. *P  0.05; **P  0.01. NS, nway disease indicate that the development and mainte-nance of AHR depends on CD4 T-cell-derived IL-13
and to a lesser extent IL-4.38 To assess the contribution of
CD4 T cells to the AHR response in FceRI	/	 mice, we
treated FceRI	/	mice with either isotype control or CD4
T-cell-depleting antibody (GK1.5) 24 hours before the
seventh OVA challenge and assessed AHR response 60
minutes after oral OVA gavage. We show that anti-CD4
treatment abrogated the AHR response in oral OVA-ga-
vaged FceRI	/	 mice compared with isotype control-
treated mice (see Supplemental Figure S2 at http://
ajp.amjpathol.org). These data indicate that the OVA
challenge-induced AHR response in FceRI	/	 mice de-
pends on CD4 T cells.
Relations between Intestinal Mast Cell Levels
and Severity of Systemic Symptoms
We were next interested in identifying immune pathways
that modulate the severity of oral antigen-induced ana-
phylaxis. Because we have demonstrated a requirement
for the IgE/FceRI/mast cell pathway in oral antigen-in-
duced anaphylaxis, we initially assessed for a relation
between levels of IgE and mast cells and the systemic
parameter of oral antigen-induced anaphylaxis severity,
hypothermia (maximum temperature change), after the
seventh oral challenge. Spearman’s rank coefficient cor-
relation analysis showed no correlation between oral an-
tigen-specific IgE levels and maximum temperature
change (results not shown); however, we did observe a
significant negative correlation between intestinal mast
cell levels and maximum temperature change (r 
	0.5377, P  0.0098), indicating a relation between in-
testinal mast cell levels and the systemic manifestations
RI/IgE dependent. Temperature change from 0 to 60 minutes and diarrhea
mice (B) after the seventh OVA challenge. Solid symbols indicate mice that
d WT and FceRI	/	 mice. Airway reactivity to methacholine was measured
thysmography. Data in B and C are represented as mean  SEM; n  4 to
icant.xis is Fc
eRI	/	
hallengeof oral antigen-induced anaphylaxis. These data indicate
0 to 60
-sensitiz
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food-induced anaphylaxis.
To begin to assess the relation between intestinal mast
cell levels and severity of anaphylaxis in WT mice we
assessed systemic (hypothermia) and intestinal (TER and
secretory diarrhea) symptoms of anaphylaxis after the
fourth oral gavage challenge. We specifically chose the
fourth oral gavage challenge because we observed an
50% penetrance of oral antigen-induced anaphylaxis in
WT mice after this challenge (see Supplemental Figure
S3 at http://ajp.amjpathol.org), and mice that do develop
anaphylaxis experience an anaphylactic reaction that
ranged frommild to moderate severity (see Supplemental
Figure S3 at http://ajp.amjpathol.org). Quantification of
systemic (hypothermia) and intestinal (TER and secretory
diarrhea) symptoms of anaphylaxis after the fourth oral
gavage challenge showed a strong correlation between
intestinal mast cell density and intestinal involvement
(TER and Isc) (Figure 4, A and B; P  0.005 and P 
0.005), which in turn correlated with cardiovascular (sys-
temic) involvement (Figure 4, C and D; P  0.005). Sim-
ilarly, levels of the mast cell activation marker mcpt-1 in
serum negatively correlated with intestinal involvement
(TER; r  	0.7, P  0.04; n  9). These data indicate
a strong relation between intestinal mast cell density
and activation and the severity of oral antigen-induced
anaphylaxis.
Intestinal Mast Cell Load Increases Severity
of Passive and Oral Antigen-Triggered
IgE-Mediated Anaphylaxis
The finding that intestinal mast cell density correlated
with increasing severity of systemic symptoms of anaphy-
laxis led us to speculate that mice with increased intes-
tinal mast cell levels would experience more severe in-
testinal and systemic symptoms of oral antigen-induced
anaphylaxis. To directly test this hypothesis, we exam-
ined severity of IgE-mediated anaphylaxis in BALB/c WT
and iIL9Tg mice. iIL9Tg mice have increased numbers of
mast cells in their intestines but not in other tissues.19
Furthermore, we observed no differences in levels of total
IgE or CD4 T-cell and B-cell function in iIL9Tg mice
Figure 4. Correlation between intestinal mast cell levels and intestinal and s
coefficient between mean number of mast cells per high-power field (hpf) in
epithelial chloride secretion (B), and between mean temperature change from
permeability change (D) after the fourth i.g. Veh or OVA challenge in OVAcompared with WT mice.19 First, we examined severity ofpassive IgE-mediated systemic anaphylaxis in BALB/c
WT and iIL9Tg mice. WT and iIL9Tg mice were injected
i.v. with 10 g of anti-IgE or isotype control antibody, and
development of shock, a systemic anaphylactic symp-
tom, was assessed by rectal thermometry. The level of
hypothermia that developed in iIL9Tg mice was signifi-
cantly elevated (ie, greater negative change in tempera-
ture) compared with WT mice (Figure 5A). Consistent with
this observation, other systemic features, including cuta-
neous and mesenteric vascular leaks and AHR, were also
significantly elevated in comparison to WT mice treated
with anti-IgE (Figure 5, B and C). The exacerbated ana-
phylaxis was specific to IgE-mediated responses be-
cause we observed comparable development of hypo-
thermia in response to i.v. anti-FcRII/III mAb injection in
these strains (Figure 6). We have previously demon-
strated that there are no differences in serum IgG levels
between strain- and littermate-matched WT and iIL9Tg
mice.19 These data indicate that increased intestinal IL-9
and mast cell numbers increase the severity of passive
IgE-mediated systemic anaphylaxis.
We next assessed whether intestinal mast cell load can
influence severity of oral antigen-triggered anaphylaxis.
WT and iIL9Tg mice were primed i.p. with OVA/alum and
subsequently challenged by repeated oral gavage with
OVA or with saline (Figure 7). Repeated administration of
OVA induced anaphylaxis with intestinal and systemic
involvement (Figures 1 and 7). Notably, the severity of the
hypothermia was significantly greater in iIL9Tg mice than
in WT mice (Figure 7). These studies indicate that ele-
vated intestinal IL-9 increases mast cell number and se-
verity of oral antigen-triggered anaphylaxis.
We have previously reported that oral antigen-trig-
gered anaphylaxis in WT mice is associated with in-
creased T helper type 2 (Th2) cytokine production and
that Th2 cytokines can exacerbate severity of anaphy-
laxis.39 To exclude the contribution of Th2 cytokines and
altered immune repertoire in IgE-mediated reactions in
iIL9Tg mice, we developed a passive oral antigen-trig-
gered anaphylaxis model to assess whether increased
intestinal mast cell levels are sufficient to increase sever-
ity of oral antigen-triggered anaphylaxis. WT and iIL9Tg
mice were injected i.v. with isotype control Ig or 10 g of
symptoms of oral antigen-induced anaphylaxis. Spearman’s rank correlation
ll intestine and small intestine epithelial permeability (TER) (A), or intestinal
minutes and intestinal epithelial chloride secretion (C), or intestinal epithelial
ed WT mice.ystemic
the smaanti-TNP IgE antibody and were administered TNP-BSA
hole-bo
ant.
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AJP April 2012, Vol. 180, No. 4(50 mg/mL; 250 L; i.g.) 24 hours later. Oral gavage of
TNP-BSA induced hypothermia in anti-TNP-IgE-treated
WT mice 10 to 15 minutes after antigen challenge (Fig-
ure 8A), which was resolved by 60 minutes (not shown).
Importantly, the kinetics of the hypothermia were compa-
rable to those observed in the active oral antigen-trig-
gered anaphylaxis model (Figure 2; results not shown).
Similarly, TNP-BSA administration to IgE anti-TNP mAb-
primed iIL9Tg mice induced hypothermia; however, the
hypothermia in these mice was significantly greater than
that observed in WT mice (Figure 8A), as was mast cell
protease production (Figure 8B). Assessment of intestinal
Figure 5. Systemic and intestinal manifestations of anti-IgE-treated WT and i
(B), and lung function (C) in BALB/c WT and iIL9Tg mice treated with isotype
treatment, mice received i.v. injection of 2% Evans blue (200 L/PBS) and w
anti-IgE injection, and airway reactivity to methacholine was measured by w
mean  SEM *P  0.05; **P  0.01. Ctrl Ig, isotype control; NS, not signific
Figure 6. Anti-FcRII/III-mediated passive systemic anaphylaxis inWT and iIL9Tg
mice. Maximum temperature change of WT and iIL9Tg mice to i.v. injection of
anti-FcRII/III mAb (clone 2.4G2) or isotype control (Ig, clone J1.2) antibody. Data
represent mean  SEM; n  4 mice per group from duplicate experiments. **P
 0.01 compared with WT control (Ctrl) Ig. Ctrl Ig, isotype control.symptoms found that neither the WT nor iIL9Tg mice
developed observable external diarrhea (results not
shown). We speculated that, although external diarrhea
in the oral antigen-triggered anaphylaxis depends on
IgE/mast cells, it may also require CD4-derived Th2
cytokine involvement to promote exaggerated peristaltic
activity.40 We therefore directly assessed basolateral ¡
apical Cl	 ion conductance of the small intestine of WT
and iIL9Tg mice ex vivo because Cl	 conductance drives
small intestine hydration and secretory diarrhea (Figure
8). Oral gavage of TNP-BSA induced a decrease in TER
in anti-TNP-IgE-treated WT mice compared with control
ice. Maximum temperature change (A), cutaneous (ear) and mesenteric leak
(Ig, clone GL117) or anti-IgE (clone EM95) antibody. B: Before the anti-IgE
sequently challenged with anti-IgE. C: WT and iIL9Tg mice received an i.v.
dy plethysmography. Number of mice are indicated. Data are presented as
Figure 7. Intestinal and systemic manifestations of oral antigen-triggered
anaphylaxis in WT and iIL9Tg mice. Temperature change from 0 to 60
minutes and diarrhea in OVA-sensitized, i.g. Veh- or OVA-challengedIL9Tg m
control
ere subBALB/c WT and iIL9Tg mice after the seventh OVA challenge. Solid symbols
indicate mice that developed diarrhea. *P  0.05; **P  0.01.
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bility (Figure 8C). Consistent with this observation, car-
bachol-induced Isc of the small intestine of WT mice
administered TNP-BSA was significantly increased com-
pared with control-treated WT mice (Figure 8D). Notably,
the TER and Isc of the small intestine of iIL9Tg mice
after carbachol stimulation was significantly greater than
that observed in WT mice administered TNP-BSA (Figure
8, C and D). To confirm that the Isc is because of
increased Cl	 conductance, we assessed Isc after phar-
macologic blockade of the apical Cl	 channel by Ca2-
activated Cl	 channel inhibitor DIDS.41,42 We show that
the carbachol-induced Isc was attenuated in the pres-
ence of DIDS, showing that oral administration of TNP-
BSA induced basolateral¡ apical Cl	 ion conductance.
These studies indicate that increased intestinal IL-9 and
mast cells predispose to increased severity to IgE-medi-
Figure 8. Passive oral antigen-triggered IgE-mediated anaphylaxis in WT
and iIL9Tg mice. Maximum temperature change (A), serum Mcpt-1 levels (B),
TER (C), and carbachol-induced change in Isc (Isc) (D) of the small intes-
tine of anti-TNP-IgE- (10 g) or control Ig- (10 g) treated WT and iIL9Tg
mice orally gavaged with TNP-BSA (50 mg/mL; 500 L). Values represent
mean  SEM; n  4 to 8 mice per group. *P  0.05; **P  0.01. Ctrl Ig,
isotype control.ated oral antigen-triggered anaphylaxis.Discussion
In the present study, we have developed a murine model
of oral antigen-induced anaphylaxis with intestinal and
systemic symptoms to assess the relative contribution of
intestinal mast cell levels to the severity of the anaphy-
lactic reaction. We show that OVA oral gavage of OVA-
primed BALB/c mice induces intestinal and systemic
symptoms of anaphylaxis. We show that the oral antigen-
triggered anaphylaxis depends on IgE-mast cell activity;
however, AHR occurred independently of IgE mast cell
activation (Figure 3C; see also Supplemental Figure S2 at
http://ajp.amjpathol.org). Notably, we show that intestinal
mast cell levels positively correlated with the severity of
systemic symptoms of anaphylaxis induced by oral anti-
gen challenge. With the use of mice with increased in-
testinal mast cells, we show that increased intestinal mast
cell load is sufficient to increase severity of both passive
and oral active IgE-mediated anaphylaxis. These data
indicate that intestinal mast cell levels may be an impor-
tant factor in the regulation of severity of the clinical
symptoms of food-induced anaphylaxis.
Intestinal and systemic signs and symptoms of food-
induced anaphylaxis in humans include diarrhea (intes-
tinal), urticaria (cutaneous), shock (cardiovascular), and
wheezing and bronchospasm (respiratory).6 We show
that oral gavage with OVA induced intestinal (diarrhea)
and systemic (cutaneous and mesenteric vascular leak,
AHR, and hypothermia) signs and symptoms of anaphy-
laxis within 60 minutes of antigen challenge. The diarrhea
was associated with increased basal Isc and carbachol-
induced Isc and was sensitive to Cl	 channel blockade,
suggesting increased basolateral ¡ luminal Cl	 secre-
tion. Notably, the diarrheal response was abrogated in
FceRI	/	 mice, indicating that this symptom depends on
IgE/FcRI signaling and mast cells. This finding is con-
sistent with the demonstration of ablation of oral antigen-
induced Isc in sensitized, mast cell-deficient mice.43–45
A number of mast cell-derived mediators, including his-
tamine, prostaglandin D2, and leukotrienes, have been
shown to modulate intestinal epithelial ion trans-
port.44,46,47 Systemic anaphylaxis in mice is predomi-
nantly a consequence of vascular leak, which causes
hypovolemic hypotension that leads to hypothermia12,17
and can be mediated by a mast cell/IgE-dependent path-
way or by an IgG-dependent pathway that involves IgG,
FcRIII, macrophages, and basophils.36,37 Notably, the
systemic symptoms could be induced in passive IgE-
induced anaphylaxis and were abrogated in FceRI	/	
mice, indicating that systemic responses depend on IgE/
FcRI signaling. We have previously reported no effect of
neutralization of FcRIIb and FcRIII pathway or IgG1
deficiency on oral antigen-induced anaphylaxis in IgG1-
deficient mice, indicating no role for the IgG pathway in
oral antigen-triggered anaphylaxis.18 These results are
consistent with human food-induced anaphylactic reac-
tions that occur within seconds to a few hours after ex-
posure to the causal food allergen7 and are associated
with IgE/mast cell activity and mast cell-derived mediator
release.8 Furthermore, anti-IgE antibodies can effectively
decrease symptoms in humans after peanut challenge.48
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sequent oral gavage with TNP-BSA in iIL9Tg mice in-
duced AHR, suggesting that IgE/mast cell activation can
promote an AHR response. The IgE-mast cell-mediated
AHR response may be mediated by mast cell-derived
mediator-induced smooth muscle contraction of the air-
way, or, alternatively, by a consequence of increased
interstitial fluid in the lung. Mast cells release a number
of mediators, including histamine, prostaglandins, leu-
kotriene C4, and IL-4, which are potent agonists for
smooth muscle contraction of airways and vascular
leak.49,5017 Previously, active systemic anaphylaxis in
mice has been associated with altered pulmonary func-
tion, including decreased pulmonary conductance and
dynamic compliance.51 Notably, the decreased pulmonary
conductance, an indicator of pulmonary obstruction from
bronchospasm, partially depended on IgE signaling,
suggesting that the IgE-mediated AHR response asso-
ciated with anaphylaxis in mice is a consequence of
bronchospasm. Note that antihistamines have been
shown to be effective for the treatment of the cutane-
ous symptoms, but not the respiratory symptoms, as-
sociated with human food-induced anaphylaxis,6 sug-
gesting the presence of parallel but independent
immune pathways that regulate different systemic
manifestations of food-induced anaphylaxis.
Although our studies indicate IgE/mast cell-dependent
pathways in the AHR response, the observation of AHR in
OVA-primed FcRI	/	mice after repeated oral gavage of
OVA indicates that AHR can also occur independently of
the IgE/FcRI/mast cell pathway. Significant experimental
evidence indicates an important contribution of CD4 T
cells in the onset of AHR associated with the asthmatic
phenotype.52–54 Consistent with this, we showed that
AHR in FcRI	/	 mice depended on CD4 T cells. How-
ever, we observed no effect of oral gavage of OVA on
pulmonary IL-4 and IL-13 levels or IL-4- and IL-13-driven
processes such as mucus hyperplasia between Veh- and
OVA-gavaged WT mice, suggesting that the CD4 T-cell
effect on the AHR response was independent of these
cytokines (results not shown). Interestingly, the AHR in-
duced by repeated oral gavage of OVA occurred in the
absence of any significant pulmonary cellular infiltrate.
Consistent with this observation, previous clinical stud-
ies describing double-blinded, placebo-controlled
food challenge of patients with food allergies have
reported the development of airway reactivity changes
in the absence of bronchopulmonary obstruction.55,56
Because asthma and atopy are considered risk factors
for severe anaphylaxis,6 we are currently investigating
the contribution of a preexisting Th2 phenotype to the
IgE-independent AHR response in oral antigen-trig-
gered anaphylaxis.
We provide experimental evidence that increased IL-9
and intestinal mast cell levels are sufficient to increase
severity of oral antigen-triggered anaphylaxis. We spec-
ulate that elevated intestinal mast cell load amplifies the
severity of oral antigen-triggered anaphylaxis by modu-
lation of oral antigen absorption and production of IgE-
induced potent autacoid mediators. We have previously
reported that iIL9Tg mice have increased intestinal para-cellular permeability.19 Altered intestinal permeability can
promote increased systemic antigen absorption and dis-
semination, which may lead to increased IgE/FcRI mast
cell degranulation and increased severity of anaphylaxis.
In support of this hypothesis, we have previously re-
ported a positive correlation between systemic antigen
dose and severity of systemic anaphylaxis.12 In addition,
ablation of susceptibility to oral antigen-triggered ana-
phylaxis was achieved through abrogation of the altered
intestinal barrier function in ilL9Tg mice.12,19 Further-
more, wheat challenge tests on patients with wheat-de-
pendent, exercise-induced anaphylaxis have shown a
positive correlation between blood gliadin levels and
clinical symptoms of exercise- and aspirin-induced
anaphylaxis.57 Intriguingly, physical exercise or intake
of aspirin promotes increases in gastrointestinal per-
meability,58,59 suggesting that altered intestinal perme-
ability may contribute to the increased severity of food-
induced anaphylaxis.
The increased severity of anaphylaxis in the iIL9Tg
mice may not necessarily pertain to mast cell-dependent
physiological effects but could simply be because of the
increased intestinal mast cell load. Moreover, iIL9Tg mice
have increased total number of intestinal mast cells; thus,
after IgE-mediated activation, they release a greater level
of mast cell-derived mediators that disseminate and in-
duce increased systemic anaphylactic symptoms. The
serum level of Mcpt-1 in the iIL9Tg mice was significantly
increased compared with WT mice, indicating increased
mast cell degranulation. Furthermore, i.v. administration
of anti-IgE antibody to iIL9Tg mice induced a greater
anaphylactic response than that observed in WT mice,
indicating that the observed increase in anaphylactic re-
action severity can occur independently from the mast
cell-induced decrease in intestinal epithelial barrier func-
tion. The increased anaphylactic response is probably a
consequence of a specific intestinal mast cell degranu-
lation because mast cell levels in other tissues, including
skin, tongue, heart, and spleen are normal (WT, 8.7 2.9
C-kit FcRI cells  103 per 106 splenocytes; iIL9Tg,
7.7  0.4 C-kit FcRI cells  103 per 106 splenocytes;
n  4 mice per group19). A clinical correlate to the iIL9Tg
mouse may be patients with mastocytosis, a proliferative
disorder of the hematopoietic mast cell progenitor lin-
eage resulting in excessive numbers of tissue mast
cells.60 Two recent, large studies consisting of a total of
320 cases of mastocytosis have reported increased risk
of developing anaphylaxis.61,62 Anaphylactic reactions
have been reported in 22% to 49% of adult and 6% to 9%
of pediatric patients with mastocytosis, whereas the life-
time prevalence in the general population is 1%.63
Development of risk assessment criteria for differenti-
ation between life-threatening and non–life-threatening
anaphylaxis is hindered by the inconsistent constellation
of symptoms present in clinical histories. Furthermore,
skin prick test and food antigen-specific IgE levels are
not necessarily predictive of susceptibility to or severity of
anaphylaxis.64 We present experimental data showing
that increased intestinal mast cell levels can increase
susceptibility and severity to oral antigen-triggered ana-
phylaxis in mice. On the basis of this evidence and sim-
Mast Cells Control Anaphylaxis Severity 1545
AJP April 2012, Vol. 180, No. 4ilarities between clinical anaphylaxis and our experimen-
tal model, investigation of the intestinal mast cell levels
and phenotypes in patients with and without a clinical
history of food-triggered anaphylaxis is warranted to as-
sess the potential predictive value of intestinal mast cells
for susceptibility to life-threatening and non–life-threaten-
ing anaphylaxis.
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